Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Janssen Biotech Inc patents


Recent patent applications related to Janssen Biotech Inc. Janssen Biotech Inc is listed as an Agent/Assignee. Note: Janssen Biotech Inc may have other listings under different names/spellings. We're not affiliated with Janssen Biotech Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "J" | Janssen Biotech Inc-related inventors


Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis

The present invention relates to compositions and methods utilizing anti-tnf antibodies having a heavy chain (hc) comprising seq id no:36 and a light chain (lc) comprising seq id no:37 for use in the safe and effective treatment of active ankylosing spondylitis (as).. . ... Janssen Biotech Inc

Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis

The present invention relates to compositions and methods utilizing anti-tnf antibodies having a heavy chain (hc) comprising seq id no:36 and a light chain (lc) comprising seq id no:37 for use in the safe and effective treatment of active psoriatic arthritis (psa).. . ... Janssen Biotech Inc

Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells

Provided herein are methods of inhibiting growth or proliferation of cells expressing cd38 by contacting the cd38-expressing cells with 1) nk cells bound to an anti-cd38 f(ab′)2 fragment and 2) an anti-cd38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) nk cells bound to an anti-cd38 f(ab′)2 fragment and 2) an anti-cd38 antibody, in either order or simultaneously.. ... Janssen Biotech Inc

Suprachoroidal injection device

An apparatus includes a body, a cannula, a conduit, and a magnetic element. The cannula extends distally from the body. ... Janssen Biotech Inc

Toll-like receptor 3 antagonists

Toll like receptor 3 (tlr3) antibody antagonists, polynucleotides encoding tlr3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.. . ... Janssen Biotech Inc

Cd137 binding fibronectin type iii domains

. . . . Fn3 domains that specifically bind to cd137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.. . ... Janssen Biotech Inc

Pd-l1 binding fibronectin type iii domains

Fn3 domains that specifically bind to pd-l1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.. . ... Janssen Biotech Inc

Cd8a-binding fibronectin type iii domains

Fibronectin type iii domains (fn3) that specifically bind to cd8a, related polynucleotides capable of encoding cd8a-specific fn3 domains, cells expressing the fn3 domains, as well as associated vectors, and detectably labeled fn3 domains are useful in therapeutic and diagnostic applications.. . ... Janssen Biotech Inc

Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces

Protein scaffolds and scaffold libraries based on a fibronectin type iii (fn3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.. . ... Janssen Biotech Inc

Method of treating psoriasis with anti-il23 specific antibody

A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an il-12/23p40 antibody by administering an il-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves pasi75, pasi90, pasi100 or iga 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.. . ... Janssen Biotech Inc

Treatment of pluripotent cells

The present invention provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3β (gsk-3b) enzyme activity.. ... Janssen Biotech Inc

Media suction devices and methods

Devices and methods are provided for removing media from a culture vessel that decreases disruption of the interface between the cellular material and media within the vessel such that aspiration and removal of cells or cell clusters along with the media is minimized. In addition, the media fluid turbulence is decreased so as to minimize the activation or disruption of cells and cell clusters.. ... Janssen Biotech Inc

Combination therapies for cd38-positive hematological malignances with anti-cd38 antibodies and cyclophosphamide

Provided are combination therapies comprising an anti-cd38 antibody and cyclophosphamide for cd38-positive hematological malignancies.. . ... Janssen Biotech Inc

Media suction devices and methods

Devices and methods are provided for removing media from a culture vessel that decreases disruption of the interface between the cellular material and media within the vessel such that aspiration and removal of cells or cell clusters along with the media is minimized. In addition, the media fluid turbulence is decreased so as to minimize the activation or disruption of cells and cell clusters.. ... Janssen Biotech Inc

04/12/18 / #20180099130

Cell encapsulation loading device

The present invention provides a loading fixture for loading cells, cell clusters, and media to an immune-isolation device. The loading fixture permits the loading of cells into the immune-isolation device without manual manipulation of the immune-isolation device, until the loading device is opened at the point of use, thereby minimizing the risk of contamination of the immune-isolation device.. ... Janssen Biotech Inc

04/12/18 / #20180099129

Cell encapsulation loading device

The present invention provides a loading fixture for loading cells, cell clusters, and media to an immune-isolation device. The loading fixture permits the loading of cells into the immune-isolation device without manual manipulation of the immune-isolation device, until the loading device is opened at the point of use, thereby minimizing the risk of contamination of the immune-isolation device.. ... Janssen Biotech Inc

04/05/18 / #20180094052

Safe and effective method of treating psoriasis with anti-il23 specific antibody

A method of treating psoriasis in a patient by administering an il-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves pasi90, pasi100 or iga 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.. . ... Janssen Biotech Inc

03/22/18 / #20180079809

Anti-il-12 antibodies, epitopes, compositions, methods and uses

An anti-il-12 antibody or fragment thereof that binds to a portion of the il-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of il-12, including isolated nucleic acids that encode at least one anti-il-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.. . ... Janssen Biotech Inc

02/15/18 / #20180044430

Fc engineered anti-tnfr superfamily member antibodies having enhanced atonistic activity and methods of using them

The present invention relates to engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them.. . ... Janssen Biotech Inc

02/15/18 / #20180044427

Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions

The present invention relates to engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions.. . ... Janssen Biotech Inc

02/08/18 / #20180036379

Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody

A method of treating an il-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of il-12/il-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.. . ... Janssen Biotech Inc

02/08/18 / #20180036336

Combination treatment for hematological cancers

The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a bcl-2 inhibitor are useful in treating hematological cancers, including aml. ... Janssen Biotech Inc

01/18/18 / #20180017586

Additive channels

Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.. ... Janssen Biotech Inc

01/18/18 / #20180017585

Additive channels

Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.. ... Janssen Biotech Inc

01/18/18 / #20180017584

Additive channels

Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.. ... Janssen Biotech Inc

01/18/18 / #20180017583

Additive channels

Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.. ... Janssen Biotech Inc

01/18/18 / #20180017582

Additive channels

Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.. ... Janssen Biotech Inc

01/18/18 / #20180015462

Additive channels

Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.. ... Janssen Biotech Inc

01/18/18 / #20180015455

Additive channels

Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.. ... Janssen Biotech Inc

01/18/18 / #20180015129

Treatment of retinal vascular disease using progenitor cells

Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.. . ... Janssen Biotech Inc

01/11/18 / #20180009854

Non-natural consensus albumin binding domains

Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients.. . ... Janssen Biotech Inc

01/04/18 / #20180002418

Interferon alpha and omega antibody antagonists

Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of ifnα and ifnω.. . ... Janssen Biotech Inc

12/21/17 / #20170362572

Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response

The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing pdx1, nkx6.1, mafa, ucn3 and slc2a. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. ... Janssen Biotech Inc

12/21/17 / #20170362316

Human anti-il-23 antibodies, compositions, methods and uses

A human anti-il-23p19 antibody, including isolated nucleic acids that encode at least one anti-il-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.. . ... Janssen Biotech Inc

12/21/17 / #20170362301

Cysteine engineered fibronectin type iii domain binding molecules

Cysteine engineered monospecific and bispecific egfr and/or c-met fn3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered fn3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered fn3 domain containing molecules; and recovering the cysteine engineered fn3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific fn3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.. ... Janssen Biotech Inc

12/21/17 / #20170360607

Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent

An apparatus includes an injector, a first fluid conduit, a second fluid line, and a control module. The injector includes a body, a flexible cannula, a flexible needle, and a sensor. ... Janssen Biotech Inc

12/21/17 / #20170360606

Injection device for subretinal delivery of therapeutic agent

An apparatus includes a pad assembly, an injector assembly, an injector driver, and a fluid source. The pad assembly is sized and configured to be placed on a forehead of a patient. ... Janssen Biotech Inc

12/21/17 / #20170360605

Guide apparatus for tangential entry into suprachoroidal space

An apparatus includes a body and a pair of rigid legs extending from the body. The body includes an engagement feature configured to engage a deployment instrument. ... Janssen Biotech Inc

12/14/17 / #20170355963

Differentiation of human pluripotent stem cells

The present invention provides a method for increasing the expression of mafa in cells expressing markers characteristic of the pancreatic endocrine lineage comprising the steps of culturing the cells expressing markers characteristic of the pancreatic endocrine lineage in medium comprising a sufficient amount of a cyclin-dependent kinase inhibitor to cause an increase in expression of mafa.. . ... Janssen Biotech Inc

12/14/17 / #20170355758

Anti-phf-tau antibodies and their uses

The present invention relates to anti-phf-tau antibodies and methods of making and using them.. . ... Janssen Biotech Inc

12/14/17 / #20170355742

Gm-csf variants and methods of use

Gm-csf variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (ibd).. . ... Janssen Biotech Inc

12/07/17 / #20170348397

Serum albumin-binding fibronectin type iii domains

Fibronectin type iii domains (fn3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific fn3 domains, cells expressing the fn3 domains, as well as associated vectors, detectably labeled fn3 domains and fn3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.. . ... Janssen Biotech Inc

11/23/17 / #20170334959

Protoxin-ii variants and methods of use

The present invention relates to protoxin-ii variants, polynucleotides encoding them, and methods of making and using the foregoing.. . ... Janssen Biotech Inc

11/16/17 / #20170327793

Differentiation of human embryonic stem cells

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater than 50% of the cells in the population co-express pdx1 and nkx6.1.. ... Janssen Biotech Inc

11/16/17 / #20170327560

Gdf15 fusion proteins and uses thereof

Fusion proteins containing a half-life extension protein, a linker, and a gdf15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.. ... Janssen Biotech Inc

11/09/17 / #20170320961

Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia

The present invention relates to combination therapies with anti-cd38 antibodies.. . ... Janssen Biotech Inc

11/09/17 / #20170320957

Methods of inhibiting activity using anti-cd27 antibodies

Human antibodies immunospecific for human cd27 are capable of blocking cd27 binding to its ligand cd70 and neutralizing bioactivity of cd27 including, but not limited to, cd27 intracellular signaling, t-cell proliferation and activation, b-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by cd70, and the production of soluble mediators from t and b-cells. The antibodies are useful in diagnosing or treating cd27 activity associated diseases and conditions.. ... Janssen Biotech Inc

10/26/17 / #20170305997

Egfr and c-met fibronectin type iii domain binding molecules

Monospecific and bispecific egfr and/or c-met fn3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.. . ... Janssen Biotech Inc

10/12/17 / #20170291942

Treatment of depression using agents that block binding of il-6 to il-6 receptor

A method for treating depression or fatigue in a subject comprises administering an agent that blocks binding of il-6 to il-6 receptor, for example, an anti-il-6 antibody or an antigen-binding fragment thereof that may comprise a heavy chain variable region and a light chain variable region of seq id no:99 and seq id no:97, respectively or a heavy chain variable region and a light chain variable region of seq id no:139 and seq id no:140, respectively. In addition, a method for determining responsiveness of an individual having depression to treatment with il-6 antibody or antigen-binding fragment thereof, comprises: (a) measuring the amount of soluble il-6 receptor (sil-6r) in a biological sample from the subject; (b) providing a threshold value correlating the amount of sil-6r and responsiveness; (c) comparing the amount of sil-6r to the threshold value to determine responsiveness; and (d) treating the individual with an agent that blocks binding of il-6 to il-6 receptor.. ... Janssen Biotech Inc

10/12/17 / #20170290912

Anti-il-23 antibodies, compositions, methods and uses

An anti-il-23 antibody, including isolated nucleic acids that encode at least one anti-il-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.. . ... Janssen Biotech Inc

09/28/17 / #20170275367

Bispecific egfr/c-met antibodies

Bispecific egfr/c-met antibodies and methods of making and using the molecules.. . ... Janssen Biotech Inc

09/14/17 / #20170260282

Gitr antibodies, methods, and uses

Provided herein are antibodies that specifically bind to gitr. Also described are related polynucleotides capable of encoding the provided gitr-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. ... Janssen Biotech Inc

09/14/17 / #20170258988

Apparatus for subretinal administration of therapeutic agent via a curved needle

An apparatus includes a body, a cannula, and a needle. The cannula is flexible and extends distally from the body. ... Janssen Biotech Inc

08/31/17 / #20170247444

Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

The present invention relates to compositions and methods utilizing anti-tnf antibodies having a heavy chain (hc) comprising seq id no:36 and a light chain (lc) comprising seq id no:37 for use in the treatment or prevention of type i diabetes (t1d).. . ... Janssen Biotech Inc

08/17/17 / #20170233461

Compositions and methods for phagocyte delivery of anti-staphylococcal agents

The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. ... Janssen Biotech Inc

08/03/17 / #20170218092

Bispecific anti-tnf-alpha/il17a antibodies and anti-tnf-alpha antibodies and methods of their use

The present invention relates to bispecific anti-tnf-α/il-17a antibodies and anti-tnf-α antibodies, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.. . ... Janssen Biotech Inc

07/27/17 / #20170210799

Anti-ror1, antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same

Provided herein are isolated antibodies that immunospecifically bind to ror1, bispecific antibodies comprising an antigen-binding site that immunospecifically binds to ror1 and an antigen-binding site that immunospecifically binds to cd3, and methods of using the same.. . ... Janssen Biotech Inc

07/20/17 / #20170204193

Antibody fc mutants with ablated effector functions

Antibody and other fc-containing molecules with variations in the fc region reduce binding to fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.. . ... Janssen Biotech Inc

06/29/17 / #20170183630

Differentiation of human embryonic stem cells

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express nkx6.1 and insulin and minimal amounts of glucagon.. ... Janssen Biotech Inc

06/29/17 / #20170183626

Defined media for expansion and maintenance of pluripotent stem cells

The present invention provides methods to promote the proliferation of undifferentiated pluripotent stem cells in defined media. Specifically, the invention provides a defined cell culture formulation for the culture, maintenance, and expansion of pluripotent stem cells, wherein culturing stem cells in the defined cell culture formulation maintains the pluripotency and karyotypic stability of the cells for at least 10 passages. ... Janssen Biotech Inc

06/29/17 / #20170183625

Differentiation of pluripotent stem cells

The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of gdf-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.. ... Janssen Biotech Inc

06/29/17 / #20170183624

Differentiation of pluripotent stem cells

The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of gdf-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.. ... Janssen Biotech Inc

06/22/17 / #20170174780

Combination therapies with anti-cd38 antibodies

The present invention relates to combination therapies with anti-cd38 antibodies.. . ... Janssen Biotech Inc

06/08/17 / #20170157247

Method of treating lupus by administering an anti-il-12 antibody

An anti-il-12 antibody that binds to a portion of the il-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of il-12, including isolated nucleic acids that encode at least one anti-il-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.. . ... Janssen Biotech Inc

06/08/17 / #20170157179

Treatment of retinal degeneration using progenitor cells

Methods and compositions for treating and reducing retinal degeneration using progenitor cells and conditioned media from progenitor cells, such as postpartum-derived cells are disclosed. Genetic factors and receptors expressed by the progenitor cells that aid in protection of retinal cells and inhibition of apoptosis of retinal cells such as photoreceptor cells are also disclosed.. ... Janssen Biotech Inc

05/04/17 / #20170121417

Subcutaneous formulations of anti-cd38 antibodies and their uses

The present invention relates to subcutaneous formulations of anti-cd38 antibodies and their uses.. . ... Janssen Biotech Inc

05/04/17 / #20170121414

Subcutaneous formulations of anti-cd38 antibodies and their uses

The present invention relates to subcutaneous formulations of anti-cd38 antibodies and their uses.. . ... Janssen Biotech Inc

05/04/17 / #20170121409

Antibodies specifically binding pd-1, tim-3 or pd-1 and tim-3 and their uses

The present invention relates to antibodies specifically binding pd-1, tim-3 or pd-1 and tim-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.. . ... Janssen Biotech Inc

04/20/17 / #20170107295

Combination therapies with anti-cd38 antibodies

The present invention relates to combination therapies with anti-cd38 antibodies and all-trans retinoic acid.. . ... Janssen Biotech Inc

04/13/17 / #20170101475

Bispecific egfr/c-met antibodies

Bispecific egfr/c-met antibodies and methods of making and using the molecules.. . ... Janssen Biotech Inc

03/30/17 / #20170088624

Agonistic antibodies specifically binding cd40 and methods of use

The present invention relates to agonistic antibodies specifically binding human cd40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.. . ... Janssen Biotech Inc

03/23/17 / #20170081634

Differentiation of human embryonic stem cells

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells, wherein greater than 85% of the cells in the population express markers characteristic of the definitive endoderm lineage.. ... Janssen Biotech Inc

03/23/17 / #20170081378

Peptide antagonist of ll-37

This disclosure is related to the peptide antagonist of ll-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of ll-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain ll-37's antibacterial activity.. ... Janssen Biotech Inc

03/23/17 / #20170080033

Treatment of retinal degeneration using progenitor cells

Methods and compositions for treating and reducing retinal degeneration using progenitor cells and conditioned media from progenitor cells, such as postpartum-derived cells are disclosed. Trophic factors and other agents secreted by the progenitor cells that protect retinal cells and inhibit apoptosis of retinal cells such as photoreceptor cells are also disclosed.. ... Janssen Biotech Inc

03/09/17 / #20170066831

St2l antagonists and methods of use

The present invention relates to st2l antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.. . ... Janssen Biotech Inc

03/02/17 / #20170058041

Toll-like receptor 3 antagonists

Toll like receptor 3 (tlr3) antibody antagonists, polynucleotides encoding tlr3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.. . ... Janssen Biotech Inc

02/16/17 / #20170044499

Differentiation of human embryonic stem cells into pancreatic endocrine cells

The present invention provides methods to promote differentiation of pancreatic endoderm cells to pancreatic endocrine rich clusters and to enhance insulin expression in hormone-expressing cells.. . ... Janssen Biotech Inc

02/16/17 / #20170044265

Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38

The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind cd38.. . ... Janssen Biotech Inc

02/16/17 / #20170044252

Anti-il-23 antibodies, compositions, methods and uses

An anti-il-23 antibody, including isolated nucleic acids that encode at least one anti-il-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.. . ... Janssen Biotech Inc

02/09/17 / #20170037136

Anti-cd154 antibodies and methods of using them

The present invention relates to antagonistic antibodies specifically binding cd154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.. . ... Janssen Biotech Inc

01/12/17 / #20170009212

Differentiation of human embryonic stem cells

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells, wherein greater than 80% of the cells in the population express markers characteristic of the definitive endoderm lineage.. ... Janssen Biotech Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Janssen Biotech Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Janssen Biotech Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###